
June 16 (Reuters) - iBio Inc IBIO.O:
IBIO INITIATES NON-HUMAN PRIMATE STUDY OF FIRST-IN-CLASS ACTIVIN E ANTIBODY FOLLOWING POSITIVE PRECLINICAL DATA DEMONSTRATING PREVENTION IN WEIGHT REGAIN AFTER GLP-1 TREATMENT
IBIO INC - IBIO-610 DRIVES 8.9% BODY WEIGHT LOSS IN MICE
IBIO INC - PRECLINICAL RESULTS SHOW 26% FAT REDUCTION WITH IBIO-610
IBIO INC - IBIO-610 PREVENTS WEIGHT REGAIN IN MICE AFTER GLP-1 THERAPY